Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Discover Agios Pharmaceuticals' Q4 2024 earnings highlights, growth plans for Pyrukynd in thalassemia & sickle cell, and insights on safety, clinical ...

Filed for Regulatory Approval of Mitapivat (PYRUKYND®) for the Treatment of Adult Patients with Non-Transfusion-Dependent and ...

Cash, cash equivalents and marketable securities as of December 31, 2024, were $1.5 billion compared to $806.4 million as of December 31, 2023.

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

After a decade of relying on blood transfusions for her congenital disorder, 11-year-old Dang Thanh Mai Thu is now recovering ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...

Mancherial: Patients of thalassemia and sickle cell are finding a respite as they are able to transfuse blood at a blood bank run by Indian Red Cross Society in Government General Hospital (GGH) for ...

Meerut: A 12-bed thalassemia ward at Saharanpur district hospital now provides free treatment to nearly 145 patients, thanks to one man's relentless fight after personal tragedy. Thalassemia is an ...